CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
about
Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell linesThe Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathwaysThe SMRT coregulator enhances growth of estrogen receptor-α-positive breast cancer cells by promotion of cell cycle progression and inhibition of apoptosis.DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer.HIF-1α deletion partially rescues defects of hematopoietic stem cell quiescence caused by Cited2 deficiency.Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast.Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrenceBridging cancer biology with the clinic: relative expression of a GRHL2-mediated gene-set pair predicts breast cancer metastasis.Quantitative proteomic analyses of mammary organoids reveals distinct signatures after exposure to environmental chemicals.CITED2 modulates estrogen receptor transcriptional activity in breast cancer cells.Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profilingCancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance.CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance.Transduction motif analysis of gastric cancer based on a human signaling network.New target genes in endometrial tumors show a role for the estrogen-receptor pathway in microsatellite-unstable cancers.Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis.RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.Integrative analysis to identify oncogenic gene expression changes associated with copy number variations of enhancer in ovarian cancer.Endocrine Resistance in Breast Cancer
P2860
Q28259553-B772CB50-A4D5-44CD-A49F-23BDA117BD49Q28854594-2CDAB9CE-AAC9-478B-82B1-C31BA0179BA9Q34068293-539B515A-10DA-49B0-8D18-3F71901FBE5EQ34484781-FA298933-BCE8-4533-8908-064F38E176D6Q35891612-5FD131EB-2A98-4A23-83AE-28B00E46DA1FQ36300973-8394A574-4FE5-4F04-ACA3-A5310D113E49Q36438653-1122BDDD-46E5-4A82-AB24-17317F7C1DAEQ36618503-C0EA3A0A-D850-4759-9855-FBFAC552EDC3Q36684669-EB09916C-F736-4B65-BA39-A2E4206CA2D4Q37178221-657625CE-2596-4AE2-A4DC-F9C47BB05795Q37458486-B598390C-D706-49B5-9F20-F2DA4EA0A597Q37472631-1E233D0B-2B57-40CC-A86E-58647473F85BQ37544330-69DCEE4E-611B-4F25-AEBB-5D8787B8F9C1Q38476822-979AA227-BD1F-4AE1-9656-F5784E7D4CEBQ38955474-33BAEA2A-B540-4CDB-8A97-E45ADAE552B5Q39527015-65EF203B-D7FA-4DA9-92D5-00DB52556D66Q41138517-8BB601C6-36AE-42EF-9ED1-16C2C006A86CQ47124134-42CDCA38-FC6F-4E9A-B684-E96AA0925CD0Q59072640-6D45FA73-0730-40CC-9409-77CF57A1FCF2
P2860
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
@en
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
@nl
type
label
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
@en
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
@nl
prefLabel
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
@en
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
@nl
P2093
P2860
P356
P1476
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer
@en
P2093
A Brinkman
A M Sieuwerts
A T den Dekker
J A Foekens
J Veldscholte
L C J Dorssers
M E Meijer-van Gelder
S Sleijfer
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605423
P407
P577
2009-11-10T00:00:00Z